Mycoplasma genitalium; pregnant women; azithromycin; macrolide resistance; 23S rRNA gene mutations; KwaZulu-Natal.

Background: Azithromycin regimens have been considered first-line treatment for Mycoplasma genitalium (M. genitalium), a sexually transmitted infection (STI) associated with adverse pregnancy outcomes. However, recent years have seen rapid emergence of macrolide resistance in M. genitalium as a resu...

Full description

Bibliographic Details
Main Authors: Meleshni Naicker, Ravesh Singh, Donald van der Westhuizen, Partson Tinarwo, Nathlee S. Abbai
Format: Article
Language:English
Published: AOSIS 2021-01-01
Series:Southern African Journal of Infectious Diseases
Subjects:
Online Access:https://sajid.co.za/index.php/sajid/article/view/209
_version_ 1818382712999772160
author Meleshni Naicker
Ravesh Singh
Donald van der Westhuizen
Partson Tinarwo
Nathlee S. Abbai
author_facet Meleshni Naicker
Ravesh Singh
Donald van der Westhuizen
Partson Tinarwo
Nathlee S. Abbai
author_sort Meleshni Naicker
collection DOAJ
description Background: Azithromycin regimens have been considered first-line treatment for Mycoplasma genitalium (M. genitalium), a sexually transmitted infection (STI) associated with adverse pregnancy outcomes. However, recent years have seen rapid emergence of macrolide resistance in M. genitalium as a result of widespread administration of azithromycin. Currently, there are limited data on macrolide resistance in pregnant women from KwaZulu-Natal (KZN), South Africa. This study investigated the prevalence of M. genitalium and emerging patterns of macrolide resistance in pregnant women from KZN. Methods: This was a sub-study of a larger study which involved laboratory-based detection of STIs in pregnant women. In the main study, pregnant women provided urine samples for detection of STIs. For this study, deoxyribose nucleic acid (DNA) extracted from stored urine was used to determine emerging macrolide resistance by amplification of the 23S ribosomal ribonucleic acid (rRNA) gene of M. genitalium by polymerase chain reaction (PCR) and sequencing of amplicons to identify mutations associated with resistance. The Allplex™ MG AziR assay was used as a confirmatory assay. Results: The prevalence of M. genitalium in pregnant women was 5.9% (13 out of 221). Sequencing of PCR amplicons did not reveal the presence of the A2059G and A2058G mutations associated with macrolide resistance. These findings were confirmed by the Allplex™ MG AziR assay. Conclusion: Despite the lack of resistance to macrolides in this study population, continued antimicrobial resistance surveillance for M. genitalium in pregnant women is important because azithromycin is now part of the South African national STI syndromic management guidelines for vaginal discharge syndrome.
first_indexed 2024-12-14T02:54:50Z
format Article
id doaj.art-806db7a564534e928474b1d73349699e
institution Directory Open Access Journal
issn 2312-0053
2313-1810
language English
last_indexed 2024-12-14T02:54:50Z
publishDate 2021-01-01
publisher AOSIS
record_format Article
series Southern African Journal of Infectious Diseases
spelling doaj.art-806db7a564534e928474b1d73349699e2022-12-21T23:19:40ZengAOSISSouthern African Journal of Infectious Diseases2312-00532313-18102021-01-01361e1e710.4102/sajid.v36i1.209167Mycoplasma genitalium; pregnant women; azithromycin; macrolide resistance; 23S rRNA gene mutations; KwaZulu-Natal.Meleshni Naicker0Ravesh Singh1Donald van der Westhuizen2Partson Tinarwo3Nathlee S. Abbai4School of Clinical Medicine Research Laboratory, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, DurbanDepartment of Medical Microbiology, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; and Department of Microbiology, National Health Laboratory Services, KwaZulu-Natal Academic Complex, Inkosi Albert Luthuli Central Hospital, DurbanInqaba Biotechnical Industries (Pty) Ltd, PretoriaDepartment of Biostatistics, College of Health Sciences, University of KwaZulu-Natal, Nelson R Mandela School of Medicine, DurbanSchool of Clinical Medicine Research Laboratory, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, DurbanBackground: Azithromycin regimens have been considered first-line treatment for Mycoplasma genitalium (M. genitalium), a sexually transmitted infection (STI) associated with adverse pregnancy outcomes. However, recent years have seen rapid emergence of macrolide resistance in M. genitalium as a result of widespread administration of azithromycin. Currently, there are limited data on macrolide resistance in pregnant women from KwaZulu-Natal (KZN), South Africa. This study investigated the prevalence of M. genitalium and emerging patterns of macrolide resistance in pregnant women from KZN. Methods: This was a sub-study of a larger study which involved laboratory-based detection of STIs in pregnant women. In the main study, pregnant women provided urine samples for detection of STIs. For this study, deoxyribose nucleic acid (DNA) extracted from stored urine was used to determine emerging macrolide resistance by amplification of the 23S ribosomal ribonucleic acid (rRNA) gene of M. genitalium by polymerase chain reaction (PCR) and sequencing of amplicons to identify mutations associated with resistance. The Allplex™ MG AziR assay was used as a confirmatory assay. Results: The prevalence of M. genitalium in pregnant women was 5.9% (13 out of 221). Sequencing of PCR amplicons did not reveal the presence of the A2059G and A2058G mutations associated with macrolide resistance. These findings were confirmed by the Allplex™ MG AziR assay. Conclusion: Despite the lack of resistance to macrolides in this study population, continued antimicrobial resistance surveillance for M. genitalium in pregnant women is important because azithromycin is now part of the South African national STI syndromic management guidelines for vaginal discharge syndrome.https://sajid.co.za/index.php/sajid/article/view/209mycoplasma genitaliumpregnant womenazithromycinmacrolide resistance23s rrna gene mutationskwazulu-natal
spellingShingle Meleshni Naicker
Ravesh Singh
Donald van der Westhuizen
Partson Tinarwo
Nathlee S. Abbai
Mycoplasma genitalium; pregnant women; azithromycin; macrolide resistance; 23S rRNA gene mutations; KwaZulu-Natal.
Southern African Journal of Infectious Diseases
mycoplasma genitalium
pregnant women
azithromycin
macrolide resistance
23s rrna gene mutations
kwazulu-natal
title Mycoplasma genitalium; pregnant women; azithromycin; macrolide resistance; 23S rRNA gene mutations; KwaZulu-Natal.
title_full Mycoplasma genitalium; pregnant women; azithromycin; macrolide resistance; 23S rRNA gene mutations; KwaZulu-Natal.
title_fullStr Mycoplasma genitalium; pregnant women; azithromycin; macrolide resistance; 23S rRNA gene mutations; KwaZulu-Natal.
title_full_unstemmed Mycoplasma genitalium; pregnant women; azithromycin; macrolide resistance; 23S rRNA gene mutations; KwaZulu-Natal.
title_short Mycoplasma genitalium; pregnant women; azithromycin; macrolide resistance; 23S rRNA gene mutations; KwaZulu-Natal.
title_sort mycoplasma genitalium pregnant women azithromycin macrolide resistance 23s rrna gene mutations kwazulu natal
topic mycoplasma genitalium
pregnant women
azithromycin
macrolide resistance
23s rrna gene mutations
kwazulu-natal
url https://sajid.co.za/index.php/sajid/article/view/209
work_keys_str_mv AT meleshninaicker mycoplasmagenitaliumpregnantwomenazithromycinmacrolideresistance23srrnagenemutationskwazulunatal
AT raveshsingh mycoplasmagenitaliumpregnantwomenazithromycinmacrolideresistance23srrnagenemutationskwazulunatal
AT donaldvanderwesthuizen mycoplasmagenitaliumpregnantwomenazithromycinmacrolideresistance23srrnagenemutationskwazulunatal
AT partsontinarwo mycoplasmagenitaliumpregnantwomenazithromycinmacrolideresistance23srrnagenemutationskwazulunatal
AT nathleesabbai mycoplasmagenitaliumpregnantwomenazithromycinmacrolideresistance23srrnagenemutationskwazulunatal